NEUROMYELITIS OPTICA SPECTRUM DISORDER
Clinical trials for NEUROMYELITIS OPTICA SPECTRUM DISORDER explained in plain language.
Never miss a new study
Get alerted when new NEUROMYELITIS OPTICA SPECTRUM DISORDER trials appear
Sign up with your email to follow new studies for NEUROMYELITIS OPTICA SPECTRUM DISORDER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take aim at autoimmune diseases
Disease control Not yet recruitingThis early-stage study is testing a new treatment called C-CAR168 for people with autoimmune diseases like multiple sclerosis, lupus, and myasthenia gravis that have not improved with standard therapies. The treatment uses a patient's own immune cells, which are modified in a lab…
Matched conditions: NEUROMYELITIS OPTICA SPECTRUM DISORDER
Phase: PHASE1 • Sponsor: The Affiliated Hospital of Qingdao University • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New hope for NMOSD patients: drug aims to slash relapse rate
Disease control Not yet recruitingThis study tests a drug called ravulizumab in about 19 Chinese adults with a rare autoimmune disease called NMOSD. The goal is to see if it can reduce the number of disease attacks (relapses) and slow disability. Participants must have had at least one attack in the past year and…
Matched conditions: NEUROMYELITIS OPTICA SPECTRUM DISORDER
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental CAR t treatment targets root cause of rare nerve disease
Disease control Not yet recruitingThis early-phase trial tests whether a new CAR T cell therapy called CC-97540 is safe for people with a rare autoimmune disease called neuromyelitis optica (NMOSD). The study will enroll 5 adults who are stable on current treatments. Researchers will check for side effects and wh…
Matched conditions: NEUROMYELITIS OPTICA SPECTRUM DISORDER
Phase: PHASE1 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New cell injection aims to tame Hard-to-Treat autoimmune nerve disorders
Disease control Not yet recruitingThis early-stage study tests a new cell therapy called HY001N in 15 adults with relapsed or treatment-resistant autoimmune neurological diseases like neuromyelitis optica. The main goal is to check safety and side effects, while also looking for signs of improvement in disability…
Matched conditions: NEUROMYELITIS OPTICA SPECTRUM DISORDER
Phase: EARLY_PHASE1 • Sponsor: Juventas Cell Therapy Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New study aims to understand physical challenges in kids with nerve diseases
Knowledge-focused Not yet recruitingThis study will look at balance, core strength, leg strength, walking ability, and fatigue in 32 children aged 6-18 with demyelinating diseases (conditions affecting the protective coating of nerves). Each child will undergo a single session of non-invasive tests like balance exe…
Matched conditions: NEUROMYELITIS OPTICA SPECTRUM DISORDER
Sponsor: Istanbul University - Cerrahpasa • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New study to uncover hidden nerve damage in NMO and MS patients
Knowledge-focused Not yet recruitingThis study will compare how often autonomic nervous system problems occur in people with neuromyelitis optica spectrum disorder (NMOSD) versus multiple sclerosis (MS). Researchers will use questionnaires and bedside heart tests to measure symptoms like dizziness, bladder issues, …
Matched conditions: NEUROMYELITIS OPTICA SPECTRUM DISORDER
Sponsor: Mohamed Moshref abd alsattar • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC